Seasonal Affective Disorder, Visual Impairment
Conditions
Keywords
pupillometry, light therapy, visual impairment, melatonin, ipRGC
Brief summary
As a subtype of major depressive disorder, seasonal affective disorder (SAD) or winter depression causes severe reductions in both quality of life and productivity and results in high morbidity and frequent sick leave (1). SAD is a prevalent disorder with rates as high as 3-5% in central European countries and 8-10% in Scandinavian countries. In our recent screening survey among persons with severe visual impairment or blindness (visual acuity \< 6/60), we found a strikingly high prevalence of SAD of 17 % compared to 8% in the fully sighted control group. Persons with maintained light perception had a highly increased SAD prevalence of 18 % whereas no light perception (NLP) respondents had an SAD prevalence of 13 %. Light is unquestionably of great importance in the development and treatment of SAD. It is suggested that a reduced retinal sensitivity to light leads to sub-threshold light input to the brain and consequently to the development of SAD. The novel retinal non-visual photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), are involved in the regulation of circadian rhythm and mood and their function are in part independent of the function of the classical rod and cone photoreceptors which form the basis of conscious visual perception. Function of the ipRGCs can be assessed by chromatic pupillometry where the sustained pupillary contractions following blue light stimulation (PIPR) is the main outcome. In persons with SAD without eye disorder the function of the ipRGCs is reduced. We here wish to investigate associations between ipRGC function and SAD symptoms, circadian profile and treatment response to light therapy in persons with visual impairment. Persons with visual impairment (SAD and non-SAD) are assessed for ipRGC function with chromatic pupillometry, for seasonal mood variation by interview and questionnaire and for diurnal melatonin secretion by saliva analysis summer and winter. In winter SAD participants are treated with daily morning bright light for 6 weeks. Reduction in depression scores and tolerability is recorded.
Interventions
DEVICElight therapy
6 weeks morning treatment with bright light therapy in own home.
Sponsors
Glostrup University Hospital, Copenhagen
Psychiatric Centre Rigshospitalet
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The outcomes assessor and the participant is unaware of ipRGC function prior to and during treatment
Intervention model description
The study combines two models: a case/control study with observational outcomes where all cases are consequently included in a non-randomized interventional study
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Seasonal affective disorder. Visual impairment (Snellen visual acuity \< 6/18) or visual field reduction (MD\<10).
Exclusion criteria
Alcohol or drug abuse. Current or planned pregnancy. Other neuropsychiatric disorder. Antidepressant medication. Regular use of melatonin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| treatment response | 6 weeks | Reduction in depression severity on the Structured interview guide for the Hamilton Depression Rating Scale - Seasonal affective disorder version (25 items version total score with range 0-78. Results from Hamilton Rating Scale for Depression 17 items (range 0-52) and the 8 item atypical symptom subscale (range 0-26) are reported. Higher scores indicate higher severity. |
| saliva melatonin concentration | 6 months | Differences in melatonin secretion as indicated by area under curve (AUC) between SAD and non-SAD (summer and winter). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PIPR - light therapy | 6 weeks | Correlation between treatment response and ipRGC function as measured by the sustained (10-20 seconds) post-illumination pupillary contraction following blue light stimulation |
Other
| Measure | Time frame | Description |
|---|---|---|
| feasibility of light therapy | 6 weeks | side effects and tolerability of light therapy |
| Late sustained post-illumination pupillary response to blue light | 6 months | Difference in late PIPR (10-30 seconds post-illumination) following high intensity blue light between SAD and non-SAD and between seasons |
Countries
Denmark
Outcome results
None listed